
Moleculin’s Global Exclusivity Reinforced: New Patent Allowances for Anticancer Drug Annamycin
Moleculin Biotech’s European Patent Extension: Moleculin Biotech, a Nasdaq-listed, late-stage pharmaceutical company, recently announced that it has received a Notice of Intent to Grant for the European patent application titled, “Method of Reconstituting Liposomal Annamycin.” This patent extension comes after the successful grant of similar patents in the United States and affirms the company’s intellectual…